NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Senti.
Just have to point out the crossing curves and the excess mortality (well, actually, excess progression, seeing as this is labelled PFS) in the Nivo arm between about 3 months and 7 months.
You know what that is, don't you...

But your point is well made.
We won't have crossing survival curves, but we will have have curves that diverge more markedly beyond 24 months.
(Hence the median is not the best metric..)

But when you get to about where we are now, diminishing returns start to set in, due to all cause mortality.